Intrinsic Value of S&P & Nasdaq Contact Us

Precigen, Inc. PGEN NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
47/100
2/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$6.00
+51.5%

Precigen, Inc. (PGEN) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Germantown, MD, United States. The current CEO is Helen Sabzevari.

PGEN has IPO date of 2013-08-08, 143 full-time employees, listed on the NASDAQ Global Select, a market capitalization of $1.19B.

About Precigen, Inc.

Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and L. lactis is a food-grade bacterium. Additionally, it provides RheoSwitch, an inducible gene switch system that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; tissue-specific promoters; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with Alaunos Therapeutics, Inc.; Ares Trading S.A.; Oragenics, Inc.; Castle Creek Biosciences, Inc.; Intrexon Energy Partners, LLC; and Intrexon Energy Partners II, LLC. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is based in Germantown, Maryland.

📍 20374 Seneca Meadows Parkway, Germantown, MD 20876 📞 301 556 9900
Company Details
SectorHealthcare
IndustryBiotechnology
CountryUnited States
ExchangeNASDAQ Global Select
CurrencyUSD
IPO Date2013-08-08
CEOHelen Sabzevari
Employees143
Trading Info
Current Price$3.96
Market Cap$1.19B
52-Week Range1.11-5.47
Beta1.12
ETFNo
ADRNo
CUSIP74017N105
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
Send us a message